

Physiomics plc
The Magdalen Centre
The Oxford Science Park
Robert Robinson Avenue
Oxford
OX4 4GA
UK

Tel 01865 784980
Fax 08701 671931

6th December 2017

Physiomics plc
("Physiomics") or ("the Company")

Issue of Equity

Physiomics plc announces today that following the receipt of notice of exercise of employee options, 1,768,815 Ordinary Shares of 0.4p each in the Company (the "Options Shares") have now been issued to the following employees at the following exercise prices:

Grantee	Number of shares issued	Exercise price per option
Dr J Millen, CEO	484,641	2.5p
Dr C Chassagnole, COO	645,231	3.5p
Dr C Chassagnole, COO	219,880	2.5p
Other staff	96,448	2.5p
Other staff	322,615	3.5p

Application has been made to admit the Option Shares to trading on AIM, and dealings in the Option Shares are expected to commence on 12th December 2017.

Following the issue of the Option Shares, the total holdings of each Director of the Company will be as follows:

Dr Paul Harper	525,707
Dr Jim Millen	684,641
Dr Christophe Chassagnole	1,017,008

Following the issue of the Option Shares, the total number of shares now in issue is 58,785,394 Ordinary Shares with voting rights attached (one vote per Share). There are no Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the Disclosure and Transparency Rules.

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name	James Millen	
2	Reason for the notification		
a)	Position/status	Director, CEO	
b)	Initial notification/ Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Physiomics plc	
b)	LEI	213800A71DSZ6ABMTQ91	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument Identification code	Ordinary share GB00BDR6W943	
b)	Nature of the transaction	Share Incentive Plan purchase	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		2.5p	484,641
d)	Aggregated information - Aggregated volume - Price	484,641 At 2.5p per share	
e)	Date of the transaction	6-12-2017	
f)	Place of the transaction	XLON, AIM	

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name	Christophe Chassagnole	
2	Reason for the notification		
a)	Position/status	Director, COO	
b)	Initial notification/ Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Physiomics plc	
b)	LEI	213800A71DSZ6ABMTQ91	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument Identification code	Ordinary share GB00BDR6W943	
b)	Nature of the transaction	Share Incentive Plan purchase	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		3.5p	645,231
		2.5p	219,880
d)	Aggregated information - Aggregated volume - Price	865,111 At 2.5p and 3.5p as shown in table above	
e)	Date of the transaction	6-12-2017	
f)	Place of the transaction	XLON, AIM	

Enquiries:

Physiomics plc

Dr Jim Millen, CEO
+44 (0)1865 784 980

WH Ireland Limited (nomad)

Katy Mitchell, James Sinclair-Ford
+44 (0) 161 832 2174

Hybridan LLP (broker)

Claire Louise Noyce
+44 (0) 203 764 2341

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.